VivoSim Labs (VIVS) Liabilities and Shareholders Equity (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Liabilities and Shareholders Equity of $7.4 million for Q1 2026, down 49.58% year-over-year from $14.6 million in Q1 2025, and up 6.12% quarter-over-quarter from $7.0 million in Q4 2025.
VivoSim Labs (VIVS) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
VivoSim Labs' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $7.4 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 49.58% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $36.0 million (up 3.72% YoY), while the FY2026 annual figure was $7.4 million, down 49.58% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $7.4 million, up from $7.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $33.3 million in Q1 2022, with the low at $3.8 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $9.7 million (2025), against an average of $14.2 million.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity plunged 79.21% in 2023, then jumped 130.74% in 2025.
- VivoSim Labs' Liabilities and Shareholders Equity stood at $25.1 million in 2022, then tumbled by 64.59% to $8.9 million in 2023, then slumped by 56.72% to $3.8 million in 2024, then jumped by 81.06% to $7.0 million in 2025, then gained by 6.12% to $7.4 million in 2026.
- Business Quant data shows VIVS's Liabilities and Shareholders Equity at $7.4 million in Q1 2026, $7.0 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.85 Mn |
| Mar 31, 2026 | 7.39 Mn |
| Dec 31, 2025 | 6.96 Mn |
| Sep 30, 2025 | 9.69 Mn |
| Jun 30, 2025 | 11.98 Mn |
| Mar 31, 2025 | 14.65 Mn |
| Dec 31, 2024 | 3.84 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 9.47 Mn |
| Mar 31, 2024 | 6.35 Mn |
| Dec 31, 2023 | 8.88 Mn |
| Sep 30, 2023 | 11.16 Mn |
| Jun 30, 2023 | 6.35 Mn |
| Mar 31, 2023 | 20.31 Mn |
| Dec 31, 2022 | 25.08 Mn |
| Sep 30, 2022 | 27.91 Mn |
| Jun 30, 2022 | 30.55 Mn |
| Mar 31, 2022 | 33.30 Mn |
| Dec 31, 2021 | 35.10 Mn |
| Sep 30, 2021 | 35.88 Mn |